2019
DOI: 10.5958/0976-5506.2019.03916.0
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of Transaminases, Total Bilirubin and Ferritin in Iraqi Thalassemia Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2021
2021

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…These therapeutic interventions include a combination of ledipasvir, daclatasvir or paritaprevir, ombitasvir and dasabuvir on the WHO list of key drugs. Such drugs changed HCV treatment and led to the use of regimens 18 .Ruhl and Everhart report that nonalcoholic fatty liver disease (NAFL) is at risk for liver damage, ranging from good fat accumulation between hepatocytes to the alcohol-induced steatohepatitis complex. No treatment for cirrhosis of the liver is accurately identified 19 .…”
Section: Discussionmentioning
confidence: 99%
“…These therapeutic interventions include a combination of ledipasvir, daclatasvir or paritaprevir, ombitasvir and dasabuvir on the WHO list of key drugs. Such drugs changed HCV treatment and led to the use of regimens 18 .Ruhl and Everhart report that nonalcoholic fatty liver disease (NAFL) is at risk for liver damage, ranging from good fat accumulation between hepatocytes to the alcohol-induced steatohepatitis complex. No treatment for cirrhosis of the liver is accurately identified 19 .…”
Section: Discussionmentioning
confidence: 99%